Recombinant interleukin-2 in metastatic renal cell carcinoma--a European multicentre phase II study.

2.50
Hdl Handle:
http://hdl.handle.net/10541/107658
Title:
Recombinant interleukin-2 in metastatic renal cell carcinoma--a European multicentre phase II study.
Authors:
von der Maase, H; Geertsen, P; Thatcher, Nick; Jasmin, C; Mercatello, A; Fosså, S D; Symann, M; Stoter, G; Nagel, G; Israel, L
Abstract:
This multinational, multicentre study represents the introduction of recombinant interleukin-2 (rIL-2) in Europe. From December 1987 to June 1989, 57 eligible patients with metastatic renal cell cancer were treated with rIL-2 administered as continuous intravenous infusion. 8 out of 51 evaluable patients responded (16%), 2 complete remission (CR) and 6 partial remission (PR). 10 patients had no change (20%). The response duration for CR was 209 and 394+ days. The median response duration for PR was 371 (range 140-506+) days. Dose-limiting grade 3-4 toxicities were hypotension in 52% of the patients, arrhythmia (4%), dyspnoea (8%), creatinine rise (4%), peripheral neurotoxicity (10%) and central neurotoxicity (10%). Toxicities most often recovered solely on interrupted therapy. 2 patients died due to catheter-related septicaemia and one patient died of rIL-2 induced renal failure. The study confirmed the antitumour efficacy of rIL-2 in renal cell cancer. Toxicities were numerous, but manageable by close observation in a normal oncology ward without routine use of an intensive care unit.
Affiliation:
Department of Oncology, Herlev University Hospital, Copenhagen, Denmark.
Citation:
Recombinant interleukin-2 in metastatic renal cell carcinoma--a European multicentre phase II study. 1991, 27 (12):1583-9 Eur J Cancer
Journal:
European Journal of Cancer
Issue Date:
1991
URI:
http://hdl.handle.net/10541/107658
PubMed ID:
1782066
Type:
Article
Language:
en
ISSN:
0959-8049
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorvon der Maase, Hen
dc.contributor.authorGeertsen, Pen
dc.contributor.authorThatcher, Nicken
dc.contributor.authorJasmin, Cen
dc.contributor.authorMercatello, Aen
dc.contributor.authorFosså, S Den
dc.contributor.authorSymann, Men
dc.contributor.authorStoter, Gen
dc.contributor.authorNagel, Gen
dc.contributor.authorIsrael, Len
dc.date.accessioned2010-07-14T17:06:57Z-
dc.date.available2010-07-14T17:06:57Z-
dc.date.issued1991-
dc.identifier.citationRecombinant interleukin-2 in metastatic renal cell carcinoma--a European multicentre phase II study. 1991, 27 (12):1583-9 Eur J Canceren
dc.identifier.issn0959-8049-
dc.identifier.pmid1782066-
dc.identifier.urihttp://hdl.handle.net/10541/107658-
dc.description.abstractThis multinational, multicentre study represents the introduction of recombinant interleukin-2 (rIL-2) in Europe. From December 1987 to June 1989, 57 eligible patients with metastatic renal cell cancer were treated with rIL-2 administered as continuous intravenous infusion. 8 out of 51 evaluable patients responded (16%), 2 complete remission (CR) and 6 partial remission (PR). 10 patients had no change (20%). The response duration for CR was 209 and 394+ days. The median response duration for PR was 371 (range 140-506+) days. Dose-limiting grade 3-4 toxicities were hypotension in 52% of the patients, arrhythmia (4%), dyspnoea (8%), creatinine rise (4%), peripheral neurotoxicity (10%) and central neurotoxicity (10%). Toxicities most often recovered solely on interrupted therapy. 2 patients died due to catheter-related septicaemia and one patient died of rIL-2 induced renal failure. The study confirmed the antitumour efficacy of rIL-2 in renal cell cancer. Toxicities were numerous, but manageable by close observation in a normal oncology ward without routine use of an intensive care unit.en
dc.language.isoenen
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshAnemia-
dc.subject.meshCarcinoma, Renal Cell-
dc.subject.meshDrug Evaluation-
dc.subject.meshFatigue-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshHypotension-
dc.subject.meshInterleukin-2-
dc.subject.meshKidney Neoplasms-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshRecombinant Proteins-
dc.subject.meshTime Factors-
dc.titleRecombinant interleukin-2 in metastatic renal cell carcinoma--a European multicentre phase II study.en
dc.typeArticleen
dc.contributor.departmentDepartment of Oncology, Herlev University Hospital, Copenhagen, Denmark.en
dc.identifier.journalEuropean Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.